Enfortumab Vedotin

證據等級: L5

預測適應症: 9 個

Enfortumab Vedotin: From Urothelial (Bladder) Cancer to Leprosy

One-Sentence Summary

Enfortumab vedotin is a Nectin‑4 targeted antibody‑drug conjugate (ADC) carrying the microtubule‑inhibitor payload MMAE, developed and used in the treatment of advanced urothelial (bladder) cancer — though this original indication is not directly recorded in the current evidence pack (original_indications is empty; only inferred from associated literature context). The TxGNN model's top-ranked new prediction, Leprosy, has a very high similarity score but zero supporting clinical trials or literature, and the evidence pack's own mechanistic review explicitly concludes there is no plausible biological link between the drug's mechanism and Mycobacterium leprae infection. This candidate should be treated as a model-only signal, not a validated repurposing opportunity.

Quick Overview

Item	Content
Original Indication	Not documented in evidence pack (`original_indications` empty); literature context (PMID 41341429) associates enfortumab vedotin ADCs with bladder/urothelial cancer — unconfirmed, pending DrugBank/label verification
Predicted New Indication	Leprosy
TxGNN Prediction Score	99.53%
Evidence Level	L5 (model prediction only, no supporting studies)
Finland Market Status	Not Marketed (未上市)
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the structured original_moa field (Data Gap DG002, High severity). Based on information embedded elsewhere in this evidence pack, enfortumab vedotin is described as a Nectin‑4 targeted antibody‑drug conjugate, whose payload MMAE (monomethyl auristatin E) is a microtubule inhibitor that acts on cancer cell mitosis — consistent with its known role as an ADC used in oncology.

For the top-ranked prediction, leprosy, the evidence pack's own repurposing rationale explicitly states there is no reasonable mechanistic link: leprosy is driven by Mycobacterium leprae infection and its associated immune/neural pathology, which has no known intersection with Nectin‑4 expression or microtubule-targeted cytotoxicity. The rationale itself notes the high TxGNN score more likely reflects an indirect node connection within the knowledge graph rather than a genuine biological mechanism.

This concern is reinforced by the quality of the broader prediction batch: of the nine ranked indications returned, all nine are rated L5/S0/Hold, two (rank 8 "infectious bovine rhinotracheitis" and rank 9 "malignant catarrh") are veterinary diseases in cattle/ruminants, explicitly flagged in the evidence pack as likely species-confusion artifacts in the knowledge graph, and one (rank 4, candidiasis) is supported only by a pharmacovigilance study describing candidiasis as an adverse safety signal of ADC-induced immunosuppression, not a treatment indication. Taken together, this pattern suggests the current prediction set for this drug reflects graph-level noise more than credible pharmacological hypotheses, and none of the top candidates — including leprosy — currently rises above a speculative, model-only signal.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

(Note: literature evidence exists elsewhere in this dataset for a different candidate indication — rank 4, "candidiasis," PMID 41341429 — but this concerns an ADC-class safety signal, not leprosy, and is discussed under Safety Considerations below.)

Finland Market Information

No marketing authorization currently registered in Finland (total_licenses: 0). Enfortumab vedotin is not currently marketed in this jurisdiction.

Cytotoxicity

Enfortumab vedotin is an antibody-drug conjugate with a cytotoxic microtubule-inhibitor payload, so this section applies.

Item	Content
Cytotoxicity Classification	Targeted therapy (Antibody-Drug Conjugate) delivering a conventional cytotoxic payload (MMAE, microtubule/mitosis inhibitor of the auristatin class)
Myelosuppression Risk	Not formally quantified in this evidence pack. A related pharmacovigilance literature signal (PMID 41341429, rank-4 candidiasis rationale) associates ADC therapy with neutropenia/immunosuppression manifesting as opportunistic infection — please refer to the package insert for confirmed data
Emetogenicity Classification	Not available in evidence pack — please refer to the package insert
Monitoring Items	CBC with differential (particularly neutrophil count), signs/symptoms of infection, liver and renal function
Handling Protection	Cytotoxic drug handling precautions should apply given the MMAE payload; confirm specific protocol against the package insert

Safety Considerations

Formal package insert data (key warnings, contraindications, DDI) is a Blocking data gap (DG001) — TFDA/manufacturer labeling has not yet been retrieved, so a full safety review cannot be completed at this time. Drug interaction screening also returned no results (ddi.query_status: not_found), which reflects absence from the queried database rather than a confirmed absence of interactions.

One relevant signal was identified in adjacent literature: a 2025 real-world FAERS pharmacovigilance study of ADCs in bladder cancer (PMID 41341429) reports safety signals including opportunistic infections such as candidiasis, plausibly related to ADC-induced immunosuppression or neutropenia. This should be treated as a risk to monitor, not a treatment indication.

Please refer to the package insert for complete safety information once available.

Conclusion and Next Steps

Decision: Hold

Rationale: The leprosy prediction has no supporting clinical trials or literature, is explicitly assessed by the evidence pack's own mechanistic analysis as lacking a plausible biological rationale, and sits within a prediction batch where all nine ranked indications are L5/Hold — two of which appear to be veterinary-disease artifacts. Combined with a Blocking-severity gap in package insert/safety data (DG001) and the drug's non-marketed status in Finland, there is currently no basis to advance this candidate beyond model screening.

To proceed, the following is needed:

TFDA/EMA package insert data (warnings, contraindications, DDI) — DG001, Blocking
Confirmed mechanism of action and original indication via DrugBank/regulatory label — DG002, High
Preclinical or biological plausibility data specifically linking Nectin‑4/MMAE activity to M. leprae infection or leprosy pathophysiology, if this hypothesis is to be pursued further
A data-quality review of the broader TxGNN prediction batch for this drug, given the presence of veterinary-disease entries (ranks 8–9) suggesting possible knowledge-graph node confusion
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.